Clay B. Siegall is the founder and Chief Executive Officer of a biotechnology company called Seattle Genetics. He is popular due to his input in the research of cancer treatments. After years of experience in the pharmaceutical industry, Siegall founded Seattle Genetics in 1998. Siegall has a Ph.D. in genetics from George Washington University. As a scientist, he has devoted most of his research time in technology that can be used in finding a cure for cancer. Besides acting as the CEO of Seattle Genetics, Clay Siegall sits on the board of trustees as the Chairman. Being a founding Father of the company, he built the company on the pillars of research, innovation, and drug development practices. These three elements combined with his constant desire to help cancer patients has seen the company rise to the top in the pharmaceutical industry. As a matter of fact, it is listed among the pioneers in the development of Antibody Drug Conjugates (ADCs).
Before founding this company, Siegall’s career began at National Institute of Health. He worked with this company for three years. He then joined Bristol-Myers Squibb Pharmaceutical and worked with them for seven years. He had also worked with the National Cancer Institute. Today, he sits on the board of trustees at Alders pharmaceutical. He is also on the board in Biopharmaceuticals. Biopharmaceuticals have played a primary role in the lives of people through its drugs.
As the CEO of Seattle Genetics, he has managed to accomplish several important things. First, the production of ADCs is a breakthrough in the fight against cancer. Antibody Drug Conjugates (ADCs) are drugs used to suppress any further growth of cancer cells. Despite rising the company a notch higher, a lot of patients have benefited from the use of this drug. Through the company’s innovative research team, the drugs have undergone series of improvements and have since been accepted in 66 nations.
Clay Siegall presence was felt during the fifth annual CHI Antibody Drug Conjugates Conference. He confirmed that drugs produced by his company had successfully contained Lymphoma in over 15,000 patients. According to Clay, the company intends to increase its workforce. As a result, projects and continuous advances will be maintained